Genetron Health and JD Health start strategic cooperation

Genetron Health, a leading domestic precision medicine company, and China's online medical and health platform JD.
com Health announced a full-scale strategic cooperation.
The two parties will deeply integrate their respective advantages to jointly create an "Internet innovation model for cancer full-cycle management
.

The cooperation between the two parties is driven by online and offline dual engines, focusing on six core contents including consumer healthcare, Internet liver disease management, government medical consortium, mutual sharing of resources for screening customers, industry and user education, and oncology center resource building
.

Based on this cooperation, HCCscreenTM will first be launched on JD Health's "520 Love Together, Care for Liver" series of popular science activities and the "618" liver cancer early screening special event, providing professional and detailed science content and early cancer screening for people at high risk of liver cancer.
At the same time, the human 8-gene mutation joint detection kit will be stationed in JD Health Internet Hospital and offline pharmacies to further improve the complete path of patient diagnosis, treatment and rehabilitation management
.

As a global cutting-edge cancer precision medicine company, Genetron Health focuses on cancer genomics research and applications, and is committed to changing cancer diagnosis and treatment methods relying on advanced molecular biology and big data analysis capabilities; JD Health, as an Internet medical health company, is committed to helping people enjoy Easy-to-obtain, convenient, high-quality and affordable medical and health products and services
.

Xin Lijun, Senior Vice President of JD Group and CEO of JD Health, said: "Relying on JD Health's full-scenario pharmaceutical supply chain and medical service capabilities and resources, we will work with Genetron Health to explore the field of early liver cancer screening and provide users with more convenient treatment.
Move the gate forward and jointly increase the penetration rate of liver cancer screening services
.

Wang Sizhen, co-founder and CEO of Genetron Biotech, said: “This cooperation means a deep integration of'Internet technology + genomics technology'.
We hope to combine the advantages of both parties to achieve the integration, upgrade and change from technology to application system.
Innovative cancer full-cycle management model, effective service to the society, and jointly promote the early realization of the goal of'Healthy China 2030'
.